Gene Solutions has entered a strategic collaboration with Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., a CAP-accredited laboratory with a strong presence across China. This partnership aims to expand access to advanced cancer diagnostics by integrating Gene Solutions’ cutting-edge oncology technologies into Topgen’s established clinical network of over 1,300 hospitals.
Topgen currently operates a comprehensive next-generation sequencing (NGS) platform and serves a broad range of hospitals throughout the country. Through this partnership, Gene Solutions will introduce several of its most advanced cancer detection and monitoring solutions to enhance Topgen’s existing offerings.
These include SPOT-MAS, Asia’s first clinically validated multi-cancer early detection (MCED) test that can identify multiple cancers from a single blood sample; SPOT-MAS Lung, a targeted screening tool for early detection of lung cancer; and K-4CARE, a genomic and transcriptomic profiling platform integrated with ctDNA-based MRD (Molecular Residual Disease) monitoring. K-4CARE supports personalized treatment planning and long-term disease tracking.
These technologies will strengthen Topgen’s oncology portfolio, enabling broader access to non-invasive, precision-driven cancer diagnostics and monitoring tools for patients across China.
Herry Shen, Chairman of Topgen’s Board, emphasized the broader impact of the alliance: “In addition to expanding our oncology portfolio with Gene Solutions’ technologies, this collaboration delivers significant strategic value. Co-developing technologies will benefit both companies, while multi-regional clinical trials and fragmentomics validation can accelerate regulatory approvals. Our shared efforts to enter international markets will also strengthen each company’s global growth strategy.”
Dr. Nguyen Hoai Nghia, CEO and Co-founder of Gene Solutions, echoed this vision: “Topgen’s extensive clinical infrastructure and nationwide reach make them an ideal partner to scale our innovations. This partnership is built to bring cutting-edge cancer genomics into everyday clinical practice, directly benefiting patients across China.”
The collaboration will focus on clinical validation, translational research, and coordinated commercialization, with the shared mission of advancing early cancer detection and improving patient outcomes across the region.